Tianjin Medical Journal ›› 2025, Vol. 53 ›› Issue (4): 389-392.doi: 10.11958/20241932

• Clinical Research • Previous Articles     Next Articles

Clinical observation of HongjinXiaojie capsule in the treatment of hematomas after minimally invasive vacuum-assisted Mammotome mastectomy

SUN Yunyun1(), MIN Meilin1,(), XU Libo2   

  1. 1 Department of Thyroid and Breast
    2 Department of Ultrasound, Wuxi Traditional Chinese Medicine Hospital, Wuxi 214000, China
  • Received:2024-11-21 Revised:2025-02-13 Published:2025-04-15 Online:2025-04-17
  • Contact: E-mail:ml570088@126.com

Abstract:

Objective To observe the efficacy of Hongjin Xiaojie capsules in treating hematoma after Mammotome minimally invasive excision and to determine the common clinical complications such as hematoma and pain after the surgery. Methods A total of 70 patients who developed hematoma within 72 hours after Mammotome minimally invasive excision for breast lumps at our hospital were selected. Based on different treatment methods, patients were divided into the observation group and the control group, with 35 cases in each group. The control group received only external hot compress treatment, while the observation group received local hot compress combined with oral administration of Hongjin Xiaojie Capsule for 4 weeks. Follow-up was conducted every 4 weeks postoperatively for a total of 12 weeks. Color ultrasound was performed to monitor the size of the hematoma. Changes in pain visual analog scale (VAS) scores and traditional Chinese medicine (TCM) syndrome scores for blood stasis were compared between the two groups of patients during follow-up. Results Four weeks after operation, the pain VAS score was significantly lower in the observation group than that in the control group [2 (1, 3) points vs. 3 (2, 4) points, P<0.05], and the proportion of hematoma was lower in the observation group than that in the control group (45.7% vs. 82.9%, P<0.05). At 12 weeks after surgery, there were no significant differences in pain scores or hematoma proportions between the two groups. The TCM symptom scores were lower in the observation group than those of the control group at 4 weeks and 12 weeks after operation (P<0.05). Conclusion Hongjin Xiaojie capsule can promote the absorption of hematoma after Mammotome surgery, effectively alleviate breast hematoma and pain, and have high safety, demonstrating broad clinical application value.

Key words: breast, hematoma, minimally invasive surgical procedures, Hongjin Xiaojie capsules, absorption and dispersion of blood stasis

CLC Number: